Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
National Institutes of Health clinical trial registry, including ClinicalTrials.gov
Ozempic (semaglutide) and other glucagon-like peptide-1 (GLP-1) receptor agonist medications target underlying issues that drive weight gain during menopause, such as insulin resistance and metabolic shifts, explains endocrinologist and obesity specialist Alex Watson, M.D
Once daily oral semaglutide tablets are taken once a day, preferably in the morning, at least 30 minutes before eating or consuming other medications
Lastly, epidemiological data suggests G6PD-d may modify several cardiovascular risk factors that can contribute to the development of ASCVD
Ongoing Research Overall, further research is needed to fully establish whether or not Ozempic can directly cause and trigger joint pain and other side effects not officially listed on the label
